{"entity":{"id":"nct04050436","kind":"trial","name":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","aka":["CERPASS"],"tldr":"A phase 2 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.","summary":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer is a phase 2 interventional study registered as NCT04050436 by Replimune, Inc., with 231 participants enrolled, started 2019-10-08 and due to reach its primary completion in 2025-09. Interventions recorded: Cemiplimab, RP1. Conditions listed: Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04050436","url":"https://clinicaltrials.gov/study/NCT04050436"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cutaneous-scc","advanced-cutaneous-scc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["replimune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04050436","phase":"2","setting":"A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","sponsor":"Replimune, Inc.","started":"2019-10-08","startedType":"actual","enrolled":231,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04050436/","neighbours":{"cancer":[{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"}]}}